Research Summary

Tafamidis Reduces Mortality in Octogenarian Patients With ATTR-CM: ACC.26 Analysis

Edited by:
Ashton L. Stahl

Key Highlights

  • Tafamidis was associated with a 49% reduction in all-cause mortality in patients ≥80 years.
  • The analysis included 1,884 patients across randomized and observational studies.
  • The findings address a critical evidence gap in elderly ATTR-CM populations.
  • Low heterogeneity across studies supports consistency of results.

Transthyretin amyloid cardiomyopathy (ATTR-CM) predominantly affects older adults, yet the benefits of disease-modifying therapy in octogenarian patients remain unclear. Findings presented at the American College of Cardiology’s Annual Scientific Session (ACC.26) demonstrate that tafamidis is associated with a significant reduction in all-cause mortality among patients aged 80 years and older. These results highlight potential clinical benefit even in a population characterized by advanced age, frailty, and limited life expectancy.

The investigators conducted a systematic review and meta-analysis to evaluate outcomes associated with tafamidis in elderly patients with transthyretin amyloidosis. A comprehensive search of PubMed, Embase, and the Cochrane Library identified studies comparing tafamidis with control groups in patients aged ≥80 years. The primary endpoint was all-cause mortality. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using a random-effects model, with statistical significance defined as P < .05. Study heterogeneity was assessed using the I² statistic.

Study Findings

The analysis included 3 studies: 1 randomized controlled trial, 1 prospective cohort study, and 1 retrospective study, encompassing a total of 1,884 patients. The mean follow-up duration ranged from 4 to 7.5 years. Across these studies, tafamidis treatment was associated with a significant reduction in all-cause mortality compared with control therapy (HR 0.51; 95% CI 0.40–0.67; P < .01).

Heterogeneity among the included studies was low (I² = 10.3%), suggesting consistent findings across different study designs and populations. These results indicate that the survival benefit observed with tafamidis in broader ATTR-CM populations may extend to patients aged 80 years and older.

Clinical Implications

According to the study authors, these findings suggest that tafamidis may provide a meaningful survival benefit in octogenarian patients with transthyretin amyloidosis, despite concerns related to advanced age and frailty. The analysis addresses an important clinical gap, as elderly patients are often underrepresented in randomized trials evaluating disease-modifying therapies.

The authors also note that further randomized controlled trials are warranted to confirm these findings in this specific population, given the reliance on observational data and the relatively small number of studies.

Expert Commentary

“These findings suggest that tafamidis use in octogenarians patients with transthyretin amyloidosis is associated with significant reduction in all-cause mortality. Further randomized controlled trials are warranted to confirm these results,” the researchers concluded.

Reference:
Santo C, Correia VM, Bueno BVK, et al. Mortality in octogenarian patients with transthyretin amyloidosis treated with tafamidis: a systematic review and meta-analysis. Presented at: American College of Cardiology Annual Scientific Session (ACC.26); March 29, 2026; New Orleans, LA.